

AEE788

Catalog No: tcsc1452



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg



Specifications

CAS No:

497839-62-0

Formula:

$C_{27}H_{32}N_6$

Pathway:

JAK/STAT Signaling;Protein Tyrosine Kinase/RTK

Target:

EGFR;EGFR

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Alternative Names:

NVP-AEE 788

Observed Molecular Weight:

440.58


Product Description

AEE788 is an inhibitor of the **EGFR** and **ErbB2** with **IC₅₀** values of 2 and 6 nM, respectively.

IC50 & Target: IC50: 2 nM (EGFR), 6 nM (ErbB2)^[1]

In Vitro: AEE788 inhibits EGFR and VEGF receptor tyrosine kinases in the nM range (IC₅₀: EGFR 2 nM, ErbB2 6 nM, KDR 77 nM, and Flt-1 59 nM). In cells, growth factor-induced EGFR and ErbB2 phosphorylation is also efficiently inhibited (IC₅₀: 11 and 220 nM, respectively). AEE788 demonstrates antiproliferative activity against a range of EGFR and ErbB2-overexpressing cell lines (including EGFRvIII-dependent lines) and inhibits the proliferation of epidermal growth factor- and VEGF-stimulated human umbilical vein endothelial cells^[1]. Treatment of cutaneous SCC cells with AEE788 leads to dose-dependent inhibition of EGFR and VEGFR-2 phosphorylation, growth inhibition, and induction of apoptosis^[2].

In Vivo: AEE788 efficiently inhibits growth factor-induced EGFR and ErbB2 phosphorylation in tumors for >72 h. AEE788 also inhibits VEGF-induced angiogenesis in a murine implant model^[1]. In mice treated with AEE788, tumor growth is inhibited by 54% at 21 days after the start of treatment compared with control mice^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!